Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, ...

Viking Therapeutics (VKTX +4.90%) is aiming to join one of the biggest growth industries of the times: the weight loss drug ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

I have always loved clothes. Gaining 46kg robbed me of my sense of style, but not my interest in fashion. Nine months on GLP-1s and a diary changed everything all over again ...

A private weight-loss clinic in London has an oddly serene waiting area. No running machines. There are no inspirational posters with before-and-after photos.

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

A new overview details emerging medical and wellness trends, underscoring advances that broaden treatment access and inform preventive care. GLP-1 drugs such as Ozempic and Wegovy extend to heart, ...

By Louise Rasmussen COPENHAGEN, Feb 18 (Reuters) - Denmark-based Arla expects a global milk surplus to drive down dairy ...